Cargando…
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
Benralizumab reduces oral corticosteroid requirements in patients with EGPA and leads to improved patient-reported outcome measures https://bit.ly/2GI0vhf
Autores principales: | Nanzer, Alexandra M., Dhariwal, Jaideep, Kavanagh, Joanne, Hearn, Andrew, Fernandes, Mariana, Thomson, Louise, Roxas, Cris, Green, Linda, D'Ancona, Grainne, Agarwal, Sangita, Kent, Brian D., Jackson, David J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7682702/ https://www.ncbi.nlm.nih.gov/pubmed/33263051 http://dx.doi.org/10.1183/23120541.00451-2020 |
Ejemplares similares
-
Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis
por: Kent, Brian D., et al.
Publicado: (2020) -
Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022) -
Emergence of extrathoracic manifestations of eosinophilic granulomatosis with polyangiitis during benralizumab treatment
por: Lim, Andy K H, et al.
Publicado: (2021) -
Eosinophilic granulomatosis with polyangiitis: case report and literature review
por: Alam, Vardah, et al.
Publicado: (2022) -
Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
por: Martínez-Rivera, Carlos, et al.
Publicado: (2021)